Tilly’S, Inc.
$172.64M- Market cap
- $50.30M
- Debt
- +$168.65M
- Cash
- −$46.31M
Capital structure 23% equity / 77% debt · EV / Revenue 0.31x
Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
FY 2026 · Mkt capMarket cap $50.30M · View financials
Snapshot Sep 8, 10:45 AM ET
FY 2025 ·
Decision snapshot: TLYS stock price at discount vs IONS $4.20 current versus $179.13 implied using P/S multiple.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at IONS's multiple
Implied fair value · at TLYS's multiple
Snapshot Sep 8, 10:41 AM ET
Metric by metric
Where each company leads, and how wide the gap is.
Growth lag
Pricing power
Operating leverage
Multiple discount
Not comparable
Lower leverage
Statements
Core statements aligned to each company's latest fiscal year.
SEC periods: TLYS FY 2026 (ended Jan 31, 2026) · IONS FY 2025 (ended Dec 31, 2025). Fiscal years are not aligned.
Trendline
Eight fiscal years of revenue, earnings, and margins before underwriting a re-rating.
Price framework
Market cap plus debt, less cash.
Capital structure 23% equity / 77% debt · EV / Revenue 0.31x
Capital structure 80% equity / 20% debt · EV / Revenue 9.28x
IONS carries the larger enterprise value at $8.76B against $172.64M; TLYS trades on the lower EV / Revenue multiple (0.31x vs 9.28x).
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
TILLY’S, INC. · implied price per share
Latest annual free cash flow must be positive to qualify the filing-backed baseline.
Ionis Pharmaceuticals, Inc. · implied price per share
Latest annual free cash flow must be positive to qualify the filing-backed baseline.
Balance sheet health
Financial health checks to separate durable balance sheets from potential value traps.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Debt / equity
Total debt against shareholders' equity
1.98x
4.59x
Net debt / EBITDA
Leverage against operating earnings
-17.50x
1.34x
Cash and equivalents
Liquid reserves on the balance sheet
$46.31M
$2.68B
Total debt
Interest-bearing obligations outstanding
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
AMERICAN EAGLE OUTFITTERS INC
TLYS vs AEO
ABERCROMBIE & FITCH CO /DE/
TLYS vs ANF
GAP INC
TLYS vs GAP
Zumiez Inc
TLYS vs ZUMZ
Sarepta Therapeutics, Inc.
TLYS vs SRPT
Moderna, Inc.
TLYS vs MRNA
Natera, Inc.
TLYS vs NTRA
ILLUMINA, INC.
TLYS vs ILMN
AMGEN INC
TLYS vs AMGN
VERTEX PHARMACEUTICALS INC / MA
TLYS vs VRTX
$168.65M
$2.24B
LLM-powered synthesis
An on-demand narrative read of the same deterministic data.
The deterministic comparison remains available. Sign in when you want an on-demand narrative synthesis of the same data.